• 1
    Morales A, Eliding D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180183.
  • 2
    Tokunoga T. Mechanism of the antitumoral effect of BCG. Annals of the Society of BCG Immunotherapy 1980; 4: 2527.
  • 3
    Böhle A, Nowc CH, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad HD. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J Urol 1990; 144: 5964.
  • 4
    Böhle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD. Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990; 144: 5358.
  • 5
    Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Intra-vesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992; 147: 16361642.
  • 6
    Holoshitz J, Koning F, Coligan JE, De Bruyn J, Strober S. Isolation of CD4 CD8 mycobacteria-reactive T lymphocyte clones from rheumatoid arthritis synovial fluid. Nature 1989; 339: 226229.
  • 7
    Seki S, Abo T, Masuda T, Ohtaki T, Kanno A, Takeda K, Rikiishi H, Nagura H, Kumagai K. Identification of activated T cell receptor lymphocytes in the liver of tumor-bearing hosts. J Clin Invest 1990; 86: 409415.
  • 8
    Hochstenbach F, Parker C, McLean J, Gieselmann V, Band H, Bank I, Chess L, Spits H, Strominger JL, Seidman JG, Brenner MB. Characterization of a third form of the human T cell receptor. J Exp Med 1988; 168: 761776.
  • 9
    Sturm E, Braakmani E, Bontrop RE, Chuchana P, Van de Griend RJ, Koning F, Lefranc MP, Bolhuis RLH. Coordinated V and Vgenesegment rearrangements in human T cell receptor γ/δ+ lymphocytes. Eur J Immunol 1989; 19: 12611265.
  • 10
    Rapp HJ. Immunotherapy of Cancer. In: AnfinsenCB, PotterM, SchechterAN, (eds) Current research in oncology. London : Academic Press, 1972: 143165.
  • 11
    Sakaki J, Kanda S, Sawamura D, Kamiya S, Inabe Y, Kawashima M. Shared antigens between BCG and tumor cells–immunotherapy with BCG for mouse tumor. Jpn J Cancer Chemother 1985; 12: 14321439.
  • 12
    Ratliff TL, Gillen D, Catalona WJ. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 1987; 137: 155158.
  • 13
    Lanier LL, Benike CJ, Philips JH, Engleman EG. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens. J Immunol 1985; 134: 794801.
  • 14
    Yagita H, Nakata M, Azuma A, Nitta T, Takeshita T, Sugamura K, Okumura K. Activation of peripheral blood T cells via the p75 interleukin 2 receptor. J Exp Med 1989; 170: 14451450.
  • 15
    Ohashi Y, Takeshita T, Nagata K, Mori S, Sugamura K. Differential expression of the IL-2 receptor subunits, p55 and p75 on various populations of primary peripheral blood mononuclear cells. J Immunol 1989; 143: 35483555.
  • 16
    Groh V, Porcelli S, Fabbi M, Lanier LL, Picker LL Anderson T, Warnke RA, Bhan AK, Strominger JL, Brenner MB. Human lymphocytes bearing T cell receptor are phenotypically diverse and evenly distributed throughout the lymphoid system. J Exp Med 1989; 169: 12771294.
  • 17
    Modlin RB, Pirmez C, Hofman FM, Torigian V, Uyemura K, Rea TH, Bloom BR, Brenner MB. Lymphocytes bearing antigen-specific T-cell receptors accumulate in human infectious disease lesions. Nature 1989; 339: 544548.
  • 18
    Nakata M, Smyth MJ, Narihisa Y, Kawasaki A, Shinkai Y, Okumura K, Yagita H. Constitutive expression of pore-forming protein in peripheral blood T cells: implication for their cytotoxic role in vivo. J Exp Med 1990; 172: 18771880.
  • 19
    Wakumoto Y, Sakamoto Y. Immunohistochemical study on the expression of perforin in tumor infiltrating lymphocytes of renal cell carcinoma. Jpn J Urol 1993; 84: 17591764.
  • 20
    Janeway CA, Jr Jones B, Hayda A. Specificity and function of T cells bearing receptors. Immunol Today 1988; 9: 7376.